This page shows the publications co-authored by David Avigan and Teru Hideshima.
MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 09; 178(6):914-926.
MUC1-C drives MYC in multiple myeloma. Blood. 2016 05 26; 127(21):2587-97.
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.